Evidence map›Paper›PMID 40321214›Full record

ArticlebioRxiv : the preprint server for biology2025

Combined quetiapine and radiation therapy approach to treat mesothelioma-initiating cells and increase survival in a mouse model of mesothelioma.

Anjelica Cardenas, Evelyn Arambula, Linda Azizi, Tara Lam, Sabrina Sutlief, Kruttika Bhat, Mohammad Saki, Ling He, Frank Pajonk

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Anjelica CardenasDepartment of Radiation Oncology, David Geffen School of Medicine at University of California Los Angeles (UCLA), Los Angeles, CA, USA.ORCID 0000-0003-4577-3253
Evelyn ArambulaDepartment of Radiation Oncology, David Geffen School of Medicine at University of California Los Angeles (UCLA), Los Angeles, CA, USA.
Linda AziziDepartment of Radiation Oncology, David Geffen School of Medicine at University of California Los Angeles (UCLA), Los Angeles, CA, USA.ORCID 0000-0002-8788-7278
Tara LamDepartment of Radiation Oncology, David Geffen School of Medicine at University of California Los Angeles (UCLA), Los Angeles, CA, USA.
Sabrina SutliefDepartment of Radiation Oncology, David Geffen School of Medicine at University of California Los Angeles (UCLA), Los Angeles, CA, USA.
Kruttika BhatDepartment of Radiation Oncology, David Geffen School of Medicine at University of California Los Angeles (UCLA), Los Angeles, CA, USA.
Mohammad SakiDepartment of Radiation Oncology, David Geffen School of Medicine at University of California Los Angeles (UCLA), Los Angeles, CA, USA.
Ling HeDepartment of Radiation Oncology, David Geffen School of Medicine at University of California Los Angeles (UCLA), Los Angeles, CA, USA.
Frank PajonkDepartment of Radiation Oncology, David Geffen School of Medicine at University of California Los Angeles (UCLA), Los Angeles, CA, USA.ORCID 0000-0003-4067-9751

Funding

Use of CTEP portfolio compounds to counteract phenotype conversion in GBMR01CA260886 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Frank Pajonk · 2022 to 2026
$2.6M
Utilizing Radiation-Induced Multi-potency to Increase the Efficacy of RadiotherapyR01CA281682 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Frank Pajonk · 2023 to 2026
$2.0M
NCI NIH HHS R01 CA260886NCI NIH HHS R01 CA281682
6 · The paper itself

Abstract

Introduction: Malignant pleural mesothelioma (MPM) is a rare thoracic cancer associated with poor prognosis and low survival rates. In solid cancers, repurposed dopamine receptor antagonists have been shown to have anti-cancer effects. Moreover, in combination with radiotherapy, quetiapine (QTP), a dopamine (D) 2/3 receptor antagonist, has been shown to interfere with self-renewal capacity in glioma-initiating cells and increase survival in mouse models of glioblastoma. In this study we explore combined treatment effects in MPM. Methods: Using mesothelioma cell lines, MSTO-211H, H2052, and H2452, and a MSTO-211H-derived orthotopic xenograft mouse model of MPM we examined how QTP combined with radiation affects mesothelioma-initiating cells (MICs) Results: We demonstrate that combining QTP with radiation reduces MIC self-renewal capacity and stem cell frequency. Conclusion: Taken together, our study highlights the therapeutic potential of radiation with QTP in the treatment of MPM.

Indexed as

cancer stem cellsdopamine antagonistIrradiationradiotherapyx-ray

Identifiers

PMID40321214
PMCPMC12047860

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.